Meltwater and Cyabra Partner to Address Dis- and Misinformation Threats to Brands 31-10-2024, 20:00

Ambiq Announces Pricing of Upsized Initial Public Offering 30-07-2025, 05:38

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T 31-05-2025, 08:00